Literature DB >> 19498408

Prostate cancer: is PSA velocity useful?

Stacy Loeb.   

Abstract

When a patient presents for assessment of prostate cancer risk, do serial measurements of PSA provide more-useful information than determination of a single PSA concentration? The authors of a new systematic review contend that the answer to this question is 'no'. Stacy Loeb cautions against hasty abandonment of PSA kinetics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19498408     DOI： 10.1038/nrurol.2009.93

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  8 in total

1.  PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.

Authors:  Paul Perrin
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

3.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

4.  Prostate specific antigen velocity threshold for predicting prostate cancer in young men.

Authors:  Stacy Loeb; Kimberly A Roehl; William J Catalona; Robert B Nadler
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

5.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

6.  PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter; H Ballentine Carter
Journal:  Eur Urol       Date:  2008-07-02       Impact factor: 20.096

Review 7.  Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.

Authors:  P Sutcliffe; S Hummel; E Simpson; T Young; A Rees; A Wilkinson; F Hamdy; N Clarke; J Staffurth
Journal:  Health Technol Assess       Date:  2009-01       Impact factor: 4.014

Review 8.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

Authors:  Andrew J Vickers; Caroline Savage; M Frank O'Brien; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
  8 in total
  2 in total

1.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

2.  Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.

Authors:  Aruna V Sarma; Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; George G Klee; Michael M Lieber; Cynthia J Girman; John M Hollingsworth; Steven J Jacobsen
Journal:  Urology       Date:  2013-10-16       Impact factor: 2.649
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.